Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Current Deferred Revenue (2016 - 2020)

NovaBay Pharmaceuticals (NBY) has disclosed Current Deferred Revenue for 10 consecutive years, with $118000.0 as the latest value for Q2 2020.

  • On a quarterly basis, Current Deferred Revenue changed N/A to $118000.0 in Q2 2020 year-over-year; TTM through Jun 2020 was $118000.0, a N/A change, with the full-year FY2019 number at $434000.0, up 958.54% from a year prior.
  • Current Deferred Revenue was $118000.0 for Q2 2020 at NovaBay Pharmaceuticals, down from $559000.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $2.5 million in Q3 2017 to a low of $41000.0 in Q4 2018.
  • A 5-year average of $948785.7 and a median of $606000.0 in 2016 define the central range for Current Deferred Revenue.
  • Peak YoY movement for Current Deferred Revenue: crashed 96.29% in 2017, then skyrocketed 958.54% in 2019.
  • NovaBay Pharmaceuticals' Current Deferred Revenue stood at $1.9 million in 2016, then plummeted by 96.29% to $69000.0 in 2017, then plummeted by 40.58% to $41000.0 in 2018, then surged by 958.54% to $434000.0 in 2019, then tumbled by 72.81% to $118000.0 in 2020.
  • Per Business Quant, the three most recent readings for NBY's Current Deferred Revenue are $118000.0 (Q2 2020), $559000.0 (Q1 2020), and $434000.0 (Q4 2019).